EventsThe 3rd International Online Conference on Clinical Medicine
Published
This submission belongs to the session S7. Pulmonology of the event The 3rd International Online Conference on Clinical Medicine
Published date
12 Nov, 2025
Academic Editor
author-avatarSukhwinder Sohal
Citation
Andreas M. Matthaiou, Nikoleta Bizymi, Ioannis Tomos, Georgios Pitsidianakis, Christos Skiadas, Adamantia Liapikou, Nikolaos Tzanakis, Katerina M. Antoniou, Plasma fibrinogen, fractional exhaled nitric oxide (FeNO), and the novel fibrinogen-to-FeNO ratio (FFR) as biomarkers in stable bronchiectasis., in Proceedings of The 3rd International Online Conference on Clinical Medicine, 17 November–19 November 2025, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Plasma fibrinogen, fractional exhaled nitric oxide (FeNO), and the novel fibrinogen-to-FeNO ratio (FFR) as biomarkers in stable bronchiectasis.

image
image
Christos Skiadas 7
image
Katerina M. Antoniou 1,2
1. Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, Heraklion, Greece, Greece
2. Department of Respiratory Medicine, University Hospital of Heraklion, Heraklion, Greece
3. 5th Department of Respiratory Medicine, Sotiria Thoracic Diseases General Hospital of Athens, Athens, Greece
4. Department of Nursing, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece
5. 5th Department of Respiratory Medicine, Sotiria Thoracic Diseases General Hospital of Athens, Athens, Greece, Greece
6. Department of Respiratory Medicine, University Hospital of Heraklion, Heraklion, Greece, Greece
7. Department of Medical Imaging, University Hospital of Heraklion, Heraklion, Greece, Greece
Abstract

Introduction: Bronchiectasis is a chronic airway disease characterized by predominantly neutrophilic and occasionally eosinophilic inflammation. We aimed to evaluate the alterations and clinical relevance of plasma fibrinogen as a key player in neutrophilic inflammation, fractional exhaled nitric oxide (FeNO) as an indicator of eosinophilic inflammation, and the fibrinogen-to-FeNO ratio (FFR) as a novel biomarker in bronchiectasis.

Methods: We conducted a two-center, observational, cross-sectional study involving a total of 45 stable, non-cystic fibrosis bronchiectasis patients. Fibrinogen, FeNO, and FFR were measured and investigated in relation to respiratory symptoms, pulmonary function, radiological extension, airway infection, systemic inflammation, and validated disease severity scores.

Results: The 45 patients (33.3% males), with a median (interquartile range, IQR) age of 71 (22.4) years, presented a median (IQR) fibrinogen of 389 (152.7) mg/dL, FeNO of 18 (15.5) ppb, and FFR of 1.2 (1.3). Fibrinogen (1) and FeNO (2) were positively or negatively statistically significantly correlated with the percentage of predicted forced expiratory volume in 1 second (FEV1%Pred, r1=-0.476/p1=0.002 and r2=+0.470/p2=0.038, respectively), total white blood cells (WBC, r1=+0.373/p1=0.012 and r2=-0.411/p2=0.013, respectively), and serum C-reactive protein (CRP, r1=+0.750/p1<0.001 and r2=-0.330/p2=0.057, respectively). Fibrinogen was additionally correlated with the number of affected lung lobes (r=+0.308/p=0.042) and erythrocyte sedimentation rate (r=+0.493/p=0.001). Interestingly, FFR was found to more strongly correlate with the FEV1%Pred (r=-0.606/p<0.001), total WBC (r=+0.471/p=0.006), serum CRP (r=+0.592/p<0.001), blood neutrophils (r=+0.357/p=0.042) and eosinophils (r=-0.390/p=0.025), and the severity of airway infection based on the isolated pathogens, including Pseudomonas aeruginosa as the cardinal pathogen (r=+0.444/p=0.034).

Conclusions: In the context of the verified clinical importance of fibrinogen and FeNO, FFR is introduced as a novel potential biomarker in bronchiectasis, reflecting the balance between neutrophilic and eosinophilic inflammation and associating with key aspects of disease activity and severity.

*AMM and NB contributed equally.

Keywords
bronchiectasis
fibrinogen
fractional exhaled nitric oxide
fibrinogen-to-FeNO ratio
biomarkers
Improving adherence to asthma medication: What are the most clinically and cost-effective strategies to improve medicine adherence in adults with asthma who are non-adherent to prescribed medicines?
Cases of Malignant Neoplasms of the Bronchi and Lungs, Their Staging and Treatment Time in Brazil: Ten Years of Analysis